Apyx Medical Inc
$ 4.69
0.86%
12 Jun - close price
- Market Cap 196,389,000 USD
- Current Price $ 4.69
- High / Low $ 4.99 / 4.63
- Stock P/E N/A
- Book Value 0.31
- EPS -0.22
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.76 %
- 52 Week High 5.08
- 52 Week Low 1.59
About
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Analyst Target Price
$6.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-10 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-13 | 2024-11-08 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.05 | -0.03 | -0.05 | 0.09 | -0.1 | -0.12 | -0.14 | -0.19 | -0.22 | -0.28 | -0.13 | -0.11 |
| Estimated EPS | -0.11 | -0.056 | -0.1033 | -0.09 | -0.12 | -0.16 | -0.19 | -0.2 | -0.21 | -0.18 | -0.11 | -0.07 |
| Surprise | 0.06 | 0.026 | 0.0533 | 0.18 | 0.02 | 0.04 | 0.05 | 0.01 | -0.01 | -0.1 | -0.02 | -0.04 |
| Surprise Percentage | 54.5455% | 46.4286% | 51.5973% | 200% | 16.6667% | 25% | 26.3158% | 5% | -4.7619% | -55.5556% | -18.1818% | -57.1429% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APYX
2026-05-27 13:38:50
Apyx Medical (NASDAQ:APYX) is returning to Miami Swim Week 2026 to showcase its Body by Apyx runway experience, featuring real patients who have undergone Renuvion® and AYON Body Contouring System™ transformations. The event highlights the company's AYON system, which integrates various liposuction modalities and Renuvion's tissue contraction technology into one platform. Apyx Medical aims to emphasize authentic results, patient confidence, and the advanced capabilities of its FDA-cleared body contouring solutions.
2026-05-21 20:09:55
Apyx Medical (APYX) announced new clinical data supporting their Avéli and Renuvion combination treatment for cellulite and skin laxity. A study involving 22 patients, published in Aesthetic Surgery Journal Open Forum, showed progressive improvement, reduced dimpling, and increased collagen and elastin levels 180 days post-treatment. This further strengthens the evidence base for Apyx Medical's Renuvion and AYON body contouring platforms.
2026-05-21 12:09:07
Apyx Medical (Nasdaq: APYX) announced new peer-reviewed clinical data showing significant improvement in cellulite appearance and skin laxity using a minimally invasive combination treatment of Avéli and Renuvion. The study found that up to 81.8% of patients experienced cellulite improvement at 180 days post-treatment, with objective 3D dimple reductions and histological evidence of increased collagen and elastin. This treatment approach addresses both the structural causes of cellulite and the quality of the skin, leading to sustained improvements.
2026-05-14 12:10:33
Apyx Medical (NASDAQ: APYX) has announced results from a retrospective 113-patient study showing that combining Renuvion with liposuction significantly improves patient satisfaction with abdominal appearance and excess skin, while also leading to lower rates of abdominoplasty and surgical revisions. The study found similar complication rates between Renuvion-assisted liposuction and liposuction alone, reinforcing Renuvion's value in aesthetic body contouring. These findings further support the company's AYON Body Contouring System, which integrates Renuvion technology.
2026-05-14 12:10:33
Apyx Medical announced a retrospective study indicating that adding Renuvion to liposuction significantly improved patient satisfaction with abdominal appearance and led to lower revision and abdominoplasty rates. The study of 113 patients showed higher satisfaction with reduced excess skin, a more than 50% reduction in abdominoplasty rates, and significantly lower revision rates, with comparable complication rates between treatment groups. This suggests Renuvion enhances outcomes without increasing adverse events.
2026-05-14 12:10:33
Apyx Medical announced the publication of a new retrospective study showing that its Renuvion technology, when used with liposuction, significantly improved patient satisfaction with abdominal appearance and reduced excess skin. The study also reported lower rates of abdominoplasty and surgical revisions, with comparable complication rates to conventional liposuction. This adds to the existing clinical evidence supporting Renuvion and highlights its value in aesthetic body contouring.
